A Trial to Evaluate BMS-298585 as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control
NCT00246987
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
341
Enrollment
INDUSTRY
Sponsor class
Conditions
Diabetes, Type 2
Interventions
DRUG:
Muraglitazar
Sponsor
Bristol-Myers Squibb